Compare AbbVie Inc (ABBV) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Raymond James Financial, Inc. — how do they compare? AbbVie Inc trades at $253.86 (market cap $449.91B), while Raymond James Financial, Inc. trades at $165.11 (market cap $32.66B). The key difference: AbbVie Inc is far larger — about 13.8× Raymond James Financial, Inc.'s market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | RJF | |
|---|---|---|
Market Cap | $449.91B | $32.66B |
Sector | Health | Financials |
52-Week High | $261.07 | $176.43 |
52-Week Low | $184.85 | $140.89 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Raymond James Financial (RJF) trades at $167.60, up 3.04% today, near its consensus price target of $168.00. The stock shows a bullish technical trend with strong moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue growth remains solid, climbing from $10.9B in 2022 to $13.84B in 2025, while net income reached $2.14B. Recent news highlights dividend declarations and record quarterly performance, reinforcing positive sentiment.
Outlook is cautiously optimistic with upside to the high target of $182.00, supported by earnings momentum and analyst coverage. Risks include rising expenses and market volatility. The stock presents a balanced opportunity for growth-oriented investors, though cost management remains a key watchpoint amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
